Lin-Wen Wu
Overview
Explore the profile of Lin-Wen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin X, Liu Y, Zhang H, Wu L, Li Q, Deng J, et al.
Cancer Cell Int
. 2023 Sep;
23(1):208.
PMID: 37742009
Lung cancer is a leading cause of cancer-related deaths, and the most common type is lung adenocarcinoma (LUAD). LUAD is frequently diagnosed in people who never smoked, patients are always...
2.
Wu L, Hu X
Anticancer Res
. 2023 Jul;
43(8):3479-3486.
PMID: 37500134
Background/aim: Hepatocellular carcinoma (HCC) currently represents the third most prevalent cause of cancer-related deaths globally. HCC is typically diagnosed at advanced stages with metastasis, and has a poor outcome. In...
3.
Li Y, Zhang M, Wu L, Liu Y, Zhang Z, Zeng L, et al.
J Biomed Sci
. 2022 Jun;
29(1):34.
PMID: 35655269
Background: Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer cases, while metastasis is considered the leading cause of HCC-related death. However, the currently available treatment strategies for efficient...
4.
Deng J, Lin X, Li Q, Cai X, Wu L, Wang W, et al.
Cancer Cell Int
. 2022 May;
22(1):189.
PMID: 35568951
Background: Inositol Polyphosphate-5-Phosphatase B (INPP5B), a inositol 5-phosphatase, plays an important role in many biological processes through phosphorylating PI(4,5)P and/or PI(3,4,5)P at the 5-position. Nevertheless, little is known about its...
5.
Zhang C, Wu L, Li Z, Zhang M, Wu J, Du F, et al.
Int J Oncol
. 2022 Mar;
60(4).
PMID: 35244188
Hypoxia promotes drug resistance and induces the expression of hypoxia inducible factor (HIF)‑1α in liver cancer cells. However, to date, no selective HIF‑1α inhibitor has been clinically approved. The aim...
6.
Li Y, Wu L, Zeng L, Zhang Z, Wang W, Zhang C, et al.
Oncogene
. 2020 Aug;
39(39):6203-6217.
PMID: 32826950
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment....
7.
Hu X, Zhang Z, Wu L, Zeng L, Chen H, Zhu H, et al.
Phytomedicine
. 2020 Feb;
68:153189.
PMID: 32070867
Background: NSCLC is the major type of lung cancer and the survival rates of NSCLC patients remain low. AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring...
8.
Li Y, Ding K, Hu X, Wu L, Zhou D, Rao M, et al.
J Cell Mol Med
. 2019 Aug;
23(11):7427-7437.
PMID: 31454149
DYRK1A is considered a potential cancer therapeutic target, but the role of DYRK1A in NSCLC oncogenesis and treatment requires further investigation. In our study, high DYRK1A expression was observed in...
9.
Wu L, Zhang J, Rao M, Zhang Z, Zhu H, Zhang C
Onco Targets Ther
. 2019 Jul;
12:4585-4593.
PMID: 31354292
Purpose: Pancreatic carcinoma is one of the most deadliest types of cancer, and relatively insensitive to the currently available chemotherapy. Thus, the discovery of novel therapeutic agents to prolong the...
10.
Li Y, Rao M, Zhang N, Wu L, Lin N, Zhang C
Exp Ther Med
. 2019 Jun;
17(6):4547-4553.
PMID: 31186678
Hepatocellular carcinoma (HCC) is associated with some of the highest cancer-associated mortality rates. Histone deacetylase (HDAC) inhibitors anti-HCC activities have been shown to promote Snail-induced metastasis. In the present study,...